6-KThe Wire
HUTCHMED (China) Ltd files 6-K
Filed Mar 23, 2026 · 3mo ago · Accession 0001648257-26-000021
Plain English
Hutchmed (China) Limited announced the initiation of a Phase III trial for HMPL-760 in patients with relapsed/refractory diffuse large B-cell lymphoma in China. This is the sole material event disclosed in this filing.
Filing details
- Company
- HUTCHMED (China) Ltd
- Ticker
- HCM
- CIK
- 1648257
- Form type
- 6-K
- Filing date
- Mar 23, 2026
- Report date
- Mar 23, 2026
- Document
- hcm-20260323x6k.htm
- Size
- 53 KB